Looking to the future: new agents for chronic hepatitis B.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 16448448.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
New antiviral agents are currently being developed to treat patients with chronic hepatitis B. Both pegylated interferon alfa-2a and entecavir are now approved for the treatment of hepatitis B while telbivudine, tenofovir, emtricitabine, and pegylated interferon alfa-2b are in clinical development. Successive advances have resulted in more profound suppression of hepatitis B replication, a reduction in breakthrough resistance, and an increase in the frequency of attainment of virologic, serologic, biochemical, and histologic clinical endpoints.
Medical subject headings
- Antiviral Agents
- Drug Carriers
- Guanine
- Hepatitis B, Chronic
- Interferon-alpha
- Polyethylene Glycols